Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.

Expert review of anticancer therapy - 1 Sept 2012

Keller-V Amsberg Gunhild, Brümmendorf Tim H

Abstract excerpt

The dual Src/Abl kinase inhibitor bosutinib (SKI-606) targets the tyrosine kinase brc-abl, the key enzyme in the development of chronic myeloid leukemia (CML). In clinical trials, bosutinib yielded promising results with regard to efficacy, tolerability and toxicity in first-, second- and third-line therapy of CML patients. Remarkably, bosutinib is able to overcome most imatinib-resistant BCR-ABL1-1 mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Biological Availability
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Diseases

Share to Imatinib Mesylate

Share to Nitriles

Share to Quinolines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 23098112
DOI: 10.1586/era.12.84

Genes

ABL1
BCR
KIT
SKI

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.PMID 23098112Read ↗

Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Semantic proximity Read ↗

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.Semantic proximity Read ↗

The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.Semantic proximity Read ↗

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Semantic proximity Read ↗

Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignanciesSemantic proximity Read ↗

New and established tyrosine kinase inhibitors for chronic myeloid leukemiaSemantic proximity Read ↗

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacySemantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

Second line small molecule therapy options for treating chronic myeloid leukemia.Semantic proximity Read ↗

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors.Semantic proximity Read ↗

New insights into small‐molecule inhibitors of Bcr‐AblSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.